Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Inhaled Extended-Release Treprostinil Product in North America

Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Inhaled Extended-Release Treprostinil Product in North America

Liquidia exclusively licenses in North America the rights to L606, an inhaled formulation of treprostinil administered twice daily with a next-generation short-acting nebulizer Liquidia funds a $10 million upfront payment from the HealthCare Royalty financing settlement Pharmosa to receive up to $215 million in development and sales milestones for PAH and PH-ILD indications, $10 million … Read more

Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Inhaled Extended-Release Treprostinil Product in North America

Liquid Corporation

Liquid Corporation Liquidia exclusively licenses in North America the rights to L606, an inhaled formulation of treprostinil administered twice daily with a next-generation short-acting nebulizer Liquidia funds a $10 million upfront payment from the HealthCare Royalty financing settlement Pharmosa to receive up to $215 million in development and sales milestones for PAH and PH-ILD indications, … Read more